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Abstract
Background: Unless metastatic or compressing the pancreatic duct, carcinoid of the pancreas are
asymptomatic showing normal levels of serotonine and its metabolites in plasma and urine, thus
resulting in delayed diagnosis and a consequent poor prognosis. However, if resection is timely
accomplished, no local recurrence might be encountered and a normal survival might be expected
in the absence of metastatic disease.
Case Presentation: The reported case of pancreatic carcinoid tumour in a 62-year-old woman
reporting only atypical symptoms consisting of intermittent epigastric pain and nausea. Urinary 5-
hydroxyindolacetic acid levels were within normal limits and only a slight elevation of serum
serotonine level was detected on admission. After tumour localisation with endoscopic
ultrasonography, left splenopancreasectomy with splenic, celiac and hepatic lymphadenectomy was
carried out.
Conclusion: The role of endoscopic ultrasonography in early detection and precise localisation of
pancreatic carcinoids, as well as the role of somatostatin-receptor scintigraphy with 111Indium
labelled pentreotide in excluding distant metastases, are confirmed. The radical resection with
lymphadenectomy is recommended in order to have a precise histological examination and detect
occult lymph node metastases.
Introduction
Although carcinoid tumours are the most frequently
occurring neuroendocrine tumours, its pancreatic locali-
sation is an exceedingly rare, and often accidental [1]. In
the largest published series of 8,305 cases of carcinoid
tumours by Modlin and Sandor [2] only 46 (0.55%) were
in the pancreas.
Unless metastatic or compressing the pancreatic duct, car-
cinoid tumours of the pancreas are asymptomatic, with
normal levels of serotonine and its metabolites in plasma
and urine [3]. Though the exact ratio of functioning versus
nonfunctioning carcinoid tumours is not yet known, for
pancreatic tumours it was estimated to be 1:10 [4]. In con-
trast, there are pancreatic carcinomas with neuroendo-
crine characteristics and carcinoid-like-symptoms [5]. For
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these reasons, a late diagnosis and a consequent poor
prognosis are usual patterns for pancreatic carcinoid. In
the Modlin and Sandor series [2], at the time of diagnosis,
76% of pancreatic carcinoid were non-localised, and the
5-year survival rate was only 34.1%.
In the recent revised classification of neuroendocrine
tumours [6] the size of 2 cm seems to be of a crucial value
over which carcinoid tumours start to exhibit a malignant
behaviour. In other words, if resection is timely accom-
plished, no local recurrence might be encountered and a
normal survival might be expected in the absence of met-
astatic disease [7].
We report a case of a primary pancreatic carcinoid with
unusual clinical presentation that induced us to describe
some insights on these infrequent tumours.
Case Report
A 62-year-old woman was referred to our Institution in
February 1999 for intermittent epigastric pain and nausea,
not always in relation to a meal. Clinical complaints of
the patient began 12 months before our observation. Dur-
ing this period, her blood tests, upper GI endoscopy and
abdominal computerised tomographic (CT) scan were
found to be normal. Abdominal ultrasonography
detected a 15 mm hypoechoic lesion in the pancreas, and
dilatation of proximal pancreatic duct. In the past, the
patient had undergone appendectomy, subtotal hysterec-
tomy, a surgical treatment of the left shoulder for trau-
matic lesion of ligaments and surgical removal of a left
benign breast nodule. During the previous year, the
patient had suffered due to left leg phebitis complicated
by minimal pulmonary embolism. She had a history of
moderate smoking and alcohol intake for a long time and
had been taking medicines (tranquillisers, vasodilators,
antacids, analgesics). There was no history of weight loss.
An abdominal examination did not evidence any
abnormality.
Her haematological and biochemical parameters were
unremarkable. Serum amylase and lipase levels were
within normal range. Serum CEA and CA 19-9 levels were
not elevated. Serum gastrin, glucagon, insulin, and
vasoactive intestinal polypeptide (VIP) levels were within
normal limits. Urinary 5-hydroxyindoleacetic acid (5-
HIAA) levels were normal, but serum serotonine level was
elevated on three occasions (430, 365 and 370 U/L respec-
tively). Repeat CT scan of the upper abdomen and an
endoscopic retrograde cholangiopancreatography failed
to reveal any pathology.
An endoscopic ultrasonography was performed with a
mechanical sector scanner (Olympus®GF-UM 20, Ham-
burg, Germany), which detected a 20 × 10 mm hypoecho-
genic tumour located at the junction of the isthmus and
body of the pancreas, confirming previous ultrasono-
graphic report (Figure 1). However, there was no sign of
proximal pancreatic duct dilatation as well as of vascular
invasion or metastatic disease, as reported on earlier ultra-
sonographic examination. Somatostatin-receptor Scintig-
raphy with 111Indium labelled pentreotide (Octroscan®,
Mallinckrodt, Petten, The Netherlands) revealed a accu-
mulation of the radioligand in the region of the suspected
tumour, and confirmed the absence of metastatic disease.
In view of a localised pancreatic neoplasm, a surgical
removal of the tumour was planned. At laparotomy, a
pancreatic tumour was found by palpation on the left side
of the portal vein. This was confirmed by intra-operative
ultrasonography which showed an hypoechogenic, well-
defined tumour, located between isthmus and corpus of
the pancreas. The rest of the pancreas appeared normal.
There was no evidence of metastasis in the liver and rest of
the peritoneal cavity. Left spleno-pancreatectomy (distal
pancreatectomy and splenectomy) with splenic, celiac
and hepatic lymphadenectomy was accomplished.
Preoperative localization of the tumour with Endoscopic  Ultrasonograhy. Figure 1
Preoperative localization of the tumour with Endoscopic 
Ultrasonograhy. Endoscopic Ultrasonography performed 
with a mechanical sector scanner (Olympus GF-UM 20, 
Hamburg, Germany) showeda hypoechogenic tumour of 10 
× 20 mm in diameter, located between the isthmus and the 
body of the pancreas with no signs of vascular invasion or 
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Gross examination (Figure 2) of the cut specimen showed
a tumour near but not compressing the pancreatic duct,
which was not dilated. There was no evident involvement
of celiac, hepatic and splenic lymph nodes. On micro-
scopic examination the cell arrangement appeared com-
patible with a neuroendocrine tumour. The argentaffin
reaction of Fontana-Masson was negative while argy-
rophil reaction of Grimelius was positive. Immunohisto-
chemistry demonstrated 100% tumour cell staining with
chromogranine, anti-NSE and anti-synaptophysine anti-
bodies. Staining with antibodies for gastrin, VIP, gluca-
gon, insulin were negative. Tumour cells displayed strong
immuno-reactivity to anti-serotonine antibodies.
The above findings on pathological examination were
conclusive of a diagnosis of a benign or low-grade malig-
nant (functioning, well differentiated, non-angioinvasive)
neuroendocrine EC cell (carcinoid) tumour of the pan-
creas in the Capella classification [6].
One year after her operation, the patient was free of symp-
toms, her serum levels of serotonine were within normal
limits and she had no signs of distant metastases.
Discussion
Carcinoid tumours cannot be considered a rare disease
any longer, with reports on large number of patients being
published in medical literature [2,8]. Their incidence
varies from 2.1 per 100,000 population per year [2] to 8.4
per 100,000 population per year [9]. It is likely that a sig-
nificant percentage of carcinoid tumours remain asymp-
tomatic and undetected during the lifetime of an
individual.
According to their embryological origin, these tumours
are classified into foregut carcinoid (respiratory tract, pan-
creas, stomach, proximal duodenum), midgut carcinoid
(jejunum, ileum, appendix, Meckel's diverticulum,
ascending colon) and hindgut carcinoid tumours (trans-
verse and descending colon, rectum) [10]. This distinction
may be useful, as carcinoid tumours from different areas
have different clinical manifestations, humoral products
and immunohistochemical features. Most of the classic
syndromes relating to the overproduction of gastrointesti-
nal and pancreatic hormones originate from foregut carci-
noid. Most of the cases are thought to secrete such low
amounts of hormones that it causes no clinical symp-
toms, and hormones hypersecretory states cannot be
detected [11].
In the present report, only a slight increase in serum sero-
tonine levels occurred without any increase in urinary lev-
els of its metabolites (5-HIAA). This is consistent with a
benign behaviour of our patient, as the tumours become
symptomatic only when hepatic metastases occur, which
manifests as classic carcinoid syndrome. It is not clear
whether such behaviour can be attributed to a benign
tumour alone or to an early stage malignant tumour too.
In classic histological terminology, carcinoid lesions are
widely regarded as malignant neoplasms, [10,12] how-
ever, there are no precise histological criteria to
distinguish benign from malignant carcinoid or the carci-
noid with metastatic potential. The possibility of a cure in
these patients is directly related to an early diagnosis.
Unfortunately, as these lesions are asymptomatic or have
non-specific clinical manifestations, as in our case the
diagnosis is often delayed. The most frequent symptoms
associated with pancreatic carcinoid tumours are abdom-
inal pain (66%) and diarrhoea (52%), related to intestinal
hypermotility [7]. In some reports [13-16] pancreatitis
seemed to be the consequence of the ductal obstruction
by the tumour, while in one report [7] a recurrent pancre-
atitis was present for more than 10 years before the onset
of the first symptoms attributed to a carcinoid. The patho-
genesis of the abdominal pain in our patient is difficult to
ascertain, as no associated pancreatitis, pancreatic duct
dilation or neural invasion were detected at the patholog-
ical examination. We suspected that symptoms in our
patient might be related to functional or transient events
in the intestine or in the pancreatic duct due to episodic
humoral or enzymatic secretions by the tumour. This is
supported by the intermittent nature of the abdominal
pain and the ultrasonographic finding of pancreatic duct
Gross appearance of the tumour in a cross-section of the  pancreatic specimen. Figure 2
Gross appearance of the tumour in a cross-section of the 
pancreatic specimen. The tumour appears well demarcated 
from the surrounding parenchyma, is near to but not stenos-
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dilation at the first instance, which was not detected on
subsequent examinations.
Endoscopic Ultrasonography is a useful test for detecting
and precisely localizing a tumour within the pancreas
[17]. Somatostatin-receptor scintigraphy with 111Indium
labeled pentreotide is useful in confirming the neuroen-
docrine mass and excluding distant metastases [18]. Both
these investigations could successfully diagnose and local-
ise the carcinoid tumour in our patient. More extensive
application of these two investigations in clinical practice
may result in early detection of neuroendocrine tumours
even in patients with no or only non-specific complaints.
Meanwhile, one should be aware of the existence of pan-
creatic carcinoid tumours. For the tumours limited to the
pancreas and no evidence of distant metastases, a radical
resection with lymphadenectomy can result in a precise
histological characterisation of tumour and detection of
occult lymph node metastases [19]. Resection at this stage
may be curative.
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